Quest Diagnostics Inc (DGX) · Oct 22, 2026 · Earnings

Quest Diagnostics earnings beat, guidance rises on volume surge

Beat — Adjusted EPS $3.00 vs ~$2.87 consensus; revenue $3.097B vs ~$3.05B

Quest Diagnostics earnings beat Q3 expectations, while higher volume and automation support a raised 2026 revenue and EPS outlook.

Quest Diagnostics is a scaled U.S. laboratory operator expanding through physician, hospital, consumer, advanced-diagnostics, acquisition, automation, and AI initiatives. Its standing growth plan already called for above-market expansion in those channels, so this filing matters because it shows that strategy converting into faster volume and a higher 2026 outlook.

The quarter cleared expectations on both major measures. Adjusted diluted EPS was $3.00 versus a published consensus of roughly $2.87, while revenue was $3.097 billion versus approximately $3.05 billion; that is a genuine earnings beat, not merely year-over-year growth. The company said it delivered 10% revenue growth and more than 15% adjusted EPS growth.

MetricQ3 2026Q3 2025 / prior guidanceRead
Revenue$3.097B$2.816B; +10.0%Beat published consensus of ~$3.05B
Adjusted diluted EPS$3.00$2.60; +15.4%Beat published consensus of ~$2.87
Requisition volume+14.5%—Main growth engine
Revenue per requisition-4.2%-2.8% prior-year comparisonPricing/mix remains a drag
Adjusted operating margin16.7%16.3%Expanded 0.4 percentage points
Nine-month operating cash flow$1.486B$1.421B; +4.6%Growth trails earnings
2026 adjusted EPS guidance$11.25-$11.35$11.05-$11.25Raised
2026 revenue guidance$12.065B-$12.105B$11.95B-$12.05BRaised

The strongest underlying signal is volume, not pricing. Requisition volume rose 14.5%, including 14.4% organic growth, while revenue per requisition fell 4.2%. That means demand and channel access are expanding materially, but Quest is accepting lower revenue per test or facing mix/pricing pressure; the quarter still produced modest adjusted-margin expansion because productivity gains and scale more than offset that drag.

Management raised the full-year bar, making the beat more consequential. The updated ranges lift the midpoint of adjusted EPS guidance by about $0.15 and the revenue midpoint by about $85 million, while expected operating cash flow rises to approximately $1.90 billion from $1.80 billion. The company explicitly tied the increase to current performance. 〔0〕

The strategic additions broaden the growth funnel but are not yet financial drivers. Quest finalized an agreement to acquire select Northeastern outreach-lab assets, added direct test-panel purchasing through Apple Health, and expanded its Alzheimer’s blood-testing menu. These initiatives reinforce its hospital, consumer, and advanced-diagnostics strategy, but the filing provides no deal price or quantified contribution, so their near-term earnings effect is not yet measurable. 〔1〕

Bottom line: This is a clean beat with a real upward revision to the 2026 outlook. The business is growing primarily through unusually strong test volume, while pricing pressure remains the main offset; overall, the filing meaningfully advances Quest’s growth story rather than merely confirming it.

Original filing on SEC EDGAR

More Quest Diagnostics Inc news

Quest Diagnostics earnings beat, guidance rises on volume surge | DGX Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.